After February market crash, ProQR will lay off 30% of its workforce and try pushing eye therapy after failed trial

A pivotal trial flop in February caused ProQR to lose nearly two-thirds of its stock value and that means the transatlantic company will officially join the dozens of biotechs and pharmas to lay off employees in the past few months.